Thus, we used a combination of a GLI1‐specific small‐molecule inhibitor, GANT58, and a CCL2/CCR2 inhibitor, INCB3344, to observe their effects on EHF‐induced CCA occurrence. Here, CCL2 is linked to cholangiocarcinoma.